Skip to main
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 25 analyst ratings
Hold
Strong Buy 8%
Buy 28%
Hold 48%
Sell 4%
Strong Sell 12%

Bulls say

Sarepta Therapeutics Inc. is positioned for potential growth, as management anticipates an inflection in annual sales that could exceed the $500 million threshold, supported by a preliminary fourth-quarter 2025 net revenue of $259.2 million, reflecting a 9% increase from the previous quarter. The company's commitment to enhancing physician engagement is expected to bolster sales outcomes, while positive initial Phase 1/2 data from its FSHD and DM1 programs could introduce further upside potential for the stock. Furthermore, the favorable risk/benefit profile of the Elevidys product suggests an ability to effectively serve both ambulatory and non-ambulatory patients, enhancing future market penetration.

Bears say

Sarepta Therapeutics Inc. has reported a preliminary fourth-quarter 2025 net revenue of $110.4 million from its Elevidys product, falling short of consensus expectations and significantly below its own annual sales floor target of $500 million, indicating pressures on its sales projections. The company's revenue model appears increasingly vulnerable, as the reported sales represent only 29% of their peak revenue achieved in the fourth quarter of 2024, raising concerns over sustained demand and market positioning. Furthermore, Sarepta's reliance on third-party manufacturing and the early-stage development of most product candidates exacerbate its operational risks and uncertainty in the efficacy of its treatments, suggesting potential long-term challenges for the company's financial stability.

Sarepta Therapeutics (SRPT) has been analyzed by 25 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 28% recommend Buy, 48% suggest Holding, 4% advise Selling, and 12% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 25 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.